Background and Aims: Chronic hepatitis B virus (HBV) infection is a major global health issue, and the prognosis of patients with HBV-associated acute-on-chronic hepatic failure (ACLF) is extremely poor. In this study, the efficacy of lamivudine was investigated in patients with ACLF. The effects of HBV DNA load and its related factors on the prognosis were also further explored.. Methods: A matched retrospective cohort study using data on ACLF patients derived from our hospital database was conducted. One hundred and thirty patients receiving lamivudine were selected into the lamivudine treatment group with another 130 without lamivudine treatment studied as control. They were matched for sex, age and imaging finding with the lamivudine treatment group. All the patients were followed up for 3 months and the survival rates were compared. The influential factors on the mortality were studied by the Cox proportional hazards model.. Results: The cumulative survival rates of patients in the ...
Chronic hepatitis B (CHB) is one of the most serious health problems affecting more than 350 million people worldwide, accounting for one million deaths every year. Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B represents a late phase in the course of the infection, which is recognized worldwide with increasing prevalence. Therapeutic intervention is often indicated for HBeAg-negative patients because spontaneous remission rarely occurs and patients usually have more advanced liver disease in comparison with HBeAg-positive patients. With the introduction of nucleos(t)ide analogues (NA), an important progress has been made regarding antiviral therapy of CHB, but the management of the HBeAg-negative type remains difficult. NA target the reverse transcriptase of hepatitis B virus (HBV) and are potent inhibitors of viral replication. Initiation of treatment in HBeAg-negative CHB usually results in a rapid decline of serum HBV DNA levels, which is often accompanied by normalization of ...
1. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. Journal of hepatology. 2012;57:167-85 2. Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z. et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of hepatology. 2016;65:700-10 3. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012;61:1754-64 4. Seetharam A, Perrillo R, Gish R. Immunosuppression in Patients with Chronic Hepatitis B. Current hepatology reports. 2014;13:235-44 5. Pang J, Zhang G, Lin Y, Xie Z, Liu H, Tang L. et al. Transforming growth factor beta-activated kinase 1 transcriptionally suppresses hepatitis B virus replication. Scientific reports. 2017;7:39901 6. Matsumoto T, Takahashi K, Inuzuka T, Kim SK, Kurosaki T, Kawakami S. et al. Activation ...
To determine the efficacy of treatment with 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon in the treatment of chronic hepatitis B in hepatitis B e antigen (HBeAg) positive adults who are in the immune tolerant phase.. To evaluate off treatment safety and sustained responses after treatment with entecavir and peginterferon alfa-2a in the treatment of chronic hepatitis B in HBeAg positive adults who are in the immune tolerant phase.. A single arm treatment study of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon alfa-2a in adults with HBeAg-positive chronic hepatitis B with normal or near normal ALT levels and high serum levels of HBV DNA (immune tolerant HBeAg-positive chronic hepatitis B). All participants will be followed until week 96 (48 weeks after discontinuation of therapy in the treatment group) at which time the primary outcome will be measured. ...
Sun, J., Hou, J.-L., Xie, Q., Li, X.-H., Zhang, J.-M., Wang, Y.-M., Wang, H., Lai, J.-Y., Chen, S.-J., Jia, J.-D., Sheng, J.-F., Chan, H. L. Y., Wang, J.-F., Li, M. K. K., Jiang, M., Popescu, M. and Sung, J. J. Y. (2011), Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Alimentary Pharmacology & Therapeutics, 34: 424-431. doi: 10.1111/j.1365-2036.2011.04750.x ...
SPEARMAN, C W N et al. South African guideline for the management of chronic hepatitis B: 2013. SAMJ, S. Afr. med. j. [online]. 2013, vol.103, n.5, pp.335-349. ISSN 2078-5135.. Hepatitis B remains a significant yet preventable health issue in South Africa. The introduction of the hepatitis B vaccine into the country some 18 years ago has demonstrated benefit, but the exposure to, and prevalence of chronic HBsAg positivity remain unacceptably high. Those with chronic hepatitis B virus infection have an elevated risk of developing cirrhosis with end-stage liver disease and a markedly elevated risk of hepatocellular carcinoma, independent of the presence of cirrhosis. The challenge in South Africa remains prevention through the universal vaccination coverage of all children and the identification of those with chronic hepatitis B virus infection. Over the last decade our understanding of hepatitis B and its behaviour and natural history in those with chronic infection has significantly improved. ...
Background & aims Virological breakthrough (VBT) could be a manifestation of chronic hepatitis B (CHB) in patients treated with long-term nucleot(s)ide analogues. We aimed to determine the association of on-treatment serum hepatitis B virus (HBV) DNA with VBT in HBeAg-positive CHB patients receiving entecavir (ETV) treatment. Methods A retrospective cohort study, including 162 consecutive patients (95 men and 67 women; mean age, 43.1±13.4 years) with HBeAg-positive CHB treated with ETV for at least 48 weeks between August 2008 and May 2015, was conducted. Univariate and multivariate cox regression analysis were used to identify associations with VBT and clinical factors, including HBV DNA and HBeAg serum status. Results Among the 162 ETV-treated HBeAg-positive CHB patients, eighteen patients (11.1%) experienced VBT (VBT group), whereas the other 144 patients were without VBT (non-VBT group). The cumulative rate of HBV DNA | 100 IU/mL in the VBT group and the non-VBT group at week 48 were 44.44% and
Abstract. Backgrounds: As one of the major public health problems, the hepatitis B virus (HBV) infection would activate the immune system. The outcome of HBV infection was affect significantly by the interactions between HBV and host immune response. Interleukins play important role in anti-viral immunity. Here we investigated the role of interleukin-35 (IL-35) in chronic HBV infection patients.. Methods/Results: Serum IL-35 in 72 chronic hepatitis B virus infection patients and 41 healthy control subjects were analyzed by ELISA assay. The mRNA level of IL-35 in PBMCs was determined by RT-qPCR. In this study, we found that both protein and mRNA levels of IL-35 were significantly decreased in chronic HBV patients compared to the healthy controls. Furthermore, the statistical analysis found that serum IL-35 was significantly associated with HBV DNA (P =0.0158), ALT (P =0.0003), AST (P =0.0216), TB (P =0.0270) and AFP (P =0.0369). Importantly, correlation analysis also found that serum IL-35 level ...
It is estimated that there are 350 million world wide carriers of the hepatitis B virus, mostly coming from Asia (Lai et al., 2005). With immigration of Chinese into Western countries, hepatitis B is now becoming established in countries where it was previously uncommon. Chronic hepatitis B infection is a prevalent disease especially in the Toronto and Vancouver areas where most Asians live. Fortunately, over the past decade effective anti-viral treatments have become available. Chronic hepatitis B is mostly an asymptomatic disease, therefore, serological and imaging tests should be used to identify, follow and treat those considered high risk ...
Chronic hepatitis B virus (HBV) infection in endemic areas usually starts since infancy and early childhood and persists lifelong. The clinical course varies among different chronic infected subjects. Majority of chronic HBV infected children present with immune-tolerant status initially, experience the immune clearance phase with various degree of liver injury during or beyond puberty, and then enter the inactive phase after hepatitis B e antigen (HBeAg) seroconversion. Part of them may have HBV DNA titers elevation with hepatitis flare after HBeAg seroconversion, the so call HBeAg-negative hepatitis flare. Liver cirrhosis, and even hepatocellular carcinoma may develop afterward. The complex course of chronic HBV infection is associated with the age/route of viral acquisition, host factors such as immune and endocrine factors, viral factors, and host-viral interactions. The adrenarche and puberty onset modulate the start of immune clearance and the severity of liver inflammation in chronic HBV infected
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir Fumitaka Suzuki,1,2 Hitomi Sezaki,1 Norio Akuta,1 Yoshiyuki Suzuki,1 Yusuke Kawamura,1 Tetsuya Hosaka,1 Masahiro Kobayashi,1 Satoshi Saitoh,1 Yasuji Arase,1 Kenji Ikeda,1 Mariko Kobayashi,3 Sachiyo Watahiki,3 Rie Mineta,3 Yukiko Suzuki,3 Hiromitsu Kumada1 1Department of Hepatology, Toranomon Hospital, Tokyo, Japan; 2Okinaka Memorial Institute for Medical Research, Tokyo, Japan; 3Research Institute for Hepatology, Toranomon Branch Hospital, Kawasaki, Japan Abstract: Tenofovir disoproxil fumarate (TDF) is widely used to treat hepatitis B virus (HBV) patients in the USA and Europe. No confirmed report of resistance selection during treatment with TDF in treatment-naïve and nucleoside/nucleotide analog-treated chronic hepatitis B patients has yet been reported. Here, we report for the first time a patient with chronic hepatitis B and cirrhosis who emerged with
To investigate dynamic fluctuations of serum viral load and peripheral T-lymphocyte subpopulations of chronic hepatitis B patients and their correlation during entecavir therapy. Fifty-five patients received entecavir 0.5 mg/d therapy. Serum HBV DNA load was measured by Real-Time-PCR, and the levels of peripheral T-lymphocyte subpopulations by flow cytometry biweekly, every four weeks and every eight weeks during weeks 1-12, 13-24 and 24-48, respectively. Multilevel modelling was used to analyse the relationship between these variables. Of the 55 patients, all HBeAg positive and with detectable HBV DNA, the majority (81.8%) had serum levels of HBV DNA over 107 copies per milliliter. HBV viral load dropped sharply during the first two weeks. In 28 and 43 patients, the level became undetectable from week 24 and 48, respectively. Using pre-therapy level as the reference, a significant decrease in CD8+ T cells and increase in CD4+ T cells were found from week 12. Both parameters and CD4+/CD8+ ratio steadily
PubMedID: 26100697 | Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response. | Antimicrobial agents and chemotherapy | 9/1/2015
B18.0 is a billable code used to specify a medical diagnosis of chronic viral hepatitis b with delta-agent. Code valid for the year 2020
Liu B, Gao W, Zhang L et al.. Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.. International immunopharmacology. Mar 2017.. Th17/Treg imbalance and the levels of related cytokines are essential in the pathogenesis of autoimmune and infectious diseases. The aim of the current study was to assess the Treg/Th17 balance and the levels of related cytokines associated with various degrees of liver injury in patients with chronic hepatitis B virus (HBV) infection.The proportions of peripheral Th17, Treg and Th1 cells in 7 patients classified as asymptomatic hepatitis B virus carriers (AsCs), 38 patients with low or moderate grade chronic hepatitis B (CHB-LM), 20 patients with chronic severe hepatitis B (CSHB), and 10 healthy controls (HCs) were determined by flow cytometry. The levels of related cytokines and the mRNA ...
This exploratory study investigated nivolumab with or without GS-4774 in patients with HBeAg negative chronic hepatitis B infection
BackgroundA recent genome-wide association study has identified a new susceptibility locus, kinesin family member 1B gene (KIF1B), strongly associated with progression from chronic hepatitis B (CHB) to hepatitis B virus-related hepatocellular carcinoma (HCC) in Chinese population, this study was carried out to explore the role of the genetic variants in KIF1B in the development of chronic hepatitis B.Methodology/Principal FindingsThree KIF1B polymorphisms (rs8019, rs17401924, and rs17401966) were selected and genotyped in 473 CHB patients and 580 controls with no history of CHB. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression model. None of these three SNPs showed association with CHBs after adjusting for age and gender. Equivalence-based method analysis confirmed the absence of association. In the further haplotype analysis, three common haplotypes were observed in this study population, but no significant effect was also found for haplotypes in the
Semi-quantitative PCR that uses non-radioactive reagents for monitoring HBV-DNA levels in chronic hepatitis B patients on interferon treatment [Abstract ...
The hepatitis B virus (HBV) cytotoxic T lymphocyte (CTL) response in patients with chronic HBV infection is generally weak or totally undetectable. This inability to mount protective CTL responses is believed to be a crucial determinant of viral persistence, and its correction represents an important objective of immune therapies for chronic hepatitis B. However, amplification of CTL responses in vivo may be ineffective if HBV-specific CD8 cells are either absent or nonresponsive to exogenous stimulation. In this study, we asked whether antiviral treatments able to inhibit viral replication and to reduce viral and antigen load can successfully reconstitute CTL responses creating the appropriate conditions for their therapeutic stimulation. For this purpose, the HBV-specific CTL response before and during lamivudine therapy was studied longitudinally in 6 HLA-A2-positive patients with HBeAg+ chronic hepatitis B. Both HBV-specific cytotoxic T cell activity measured by chromium release assay on peptide
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis ...
In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be
The mechanisms of hepatitis B virus (HBV) persistent infection are not completely understood. Interleukin (IL)-35, which is a newly identified cytokine belongs to IL-12 family, has been demonstrated to induce immunotolerance. Thus, the aim of current study was to investigate the role of IL-35 during chronic HBV infection. A total of 61 patients with chronic HBV infection (37 chronic hepatitis B [CHB] and 24 asymptomatic HBV carriers [ASC]) and 20 healthy individuals were enrolled. IL-35 concentration as well as the modulatory function of IL-35 on CD4+CD25+CD127dim/- regulatory T cells (Tregs) and on HBV antigen-specific CD8+ T cells was investigated. IL-35 expression was significantly increased in both CHB and ASC, and was positively correlated with the levels of HBV DNA. Inhibition of viral replication induced the reduction in serum levels of IL-35. IL-35 stimulation led to inhibition of proinflammatory cytokine productions and elevation of apoptosis in peripheral blood mononuclear cells, but not in
TY - JOUR. T1 - Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B. T2 - No additional benefit of combination with lamivudine. AU - van Zonneveld, Monika. AU - Zondervan, Pieter E.. AU - Cakaloglu, Yilmaz. AU - Simon, Christopher. AU - Akarca, Ulus S.. AU - So, Thomas M K. AU - Flink, Hajo J.. AU - de Man, Robert A.. AU - Schalm, Solko W.. AU - Janssen, Harry L A. AU - Niesters, H. G M. AU - Hansen, B.. AU - Vroom, B. C M. AU - van Nieuwkerk, C. M J. AU - de Vries, R. A.. AU - Jansen, J.. AU - Drenth, J.. AU - van den Hazel, S. J.. AU - den Ouden-Muller, J. W.. AU - Tan, A. C.. AU - Adler, D. M.. AU - Michielsen, P.. AU - van Vlierberghe, H.. AU - Nevens, F.. AU - Delwaide, J.. AU - Henrion, J.. AU - Zeuzem, S.. AU - Gerken, G.. AU - Bein, S.. AU - Treichel, U.. AU - Trojan, J.. AU - Manns, M. P.. AU - Hadem, J.. AU - Niederau, J.. AU - Buhl, M. R.. AU - Hansen, I. M.. AU - Krogsgaard, K.. AU - Cianciara, J.. AU - Jablonska, J.. AU - Kozlowska, J.. AU - ...
Manuscript Accepted: 16 SEP 2013. Keywords: HBV; inactive carriers; metabolic syndrome; fibrosis; FibroScan. Abstract\. Background and Aim. There are few data of fibrosis development in chronic hepatitis B (CHB) patients classified as inactive carriers. The aim of this study is to determinate the prevalence of significant fibrosis and probable cirrhosis measured by FibroScan in real inactive CHB carriers and investigate the relationship with virological, epidemiological and metabolic factors.. Methods. Cross-sectional cohort study including CHB inactive carriers. Liver stiffness measurement was performed with transient elastography (FibroScan). Significant fibrosis (≥F2) was defined as stiffness ,7.5 kPa, and probable cirrhosis as ,11.8 kPa. Factors associated with significant fibrosis were explored with univariate and multivariate adjusted logistic regression analyses.. Results. 96 CHB inactive carriers were analyzed. Of them, 24 (25%) had significant fibrosis and 7 (7%) probable cirrhosis; ...
Treatment of chronic hepatitis B (CHB) has greatly improved with the availability of nucleos(t)ide analogs (NA), which target the viral polymerase [1], [2], [3]. The sustained suppression of serum hepatitis B virus (HBV) DNA to very low or undetectable levels by these drugs has been shown to be associated with the prevention of progression of liver disease and inhibition of the development of hepatocellular carcinoma [4], [5], [6], [7]. A major shortcoming is the low rate of HBsAg loss and high rate of virological relapse when treatment is discontinued or interrupted due to low adherence [8], [9], necessitating long, and in many cases, indefinite treatment. Unfortunately, as the duration of NA treatment is prolonged, the risk of development of drug resistance increases with lesser potent and lower genetic barrier drugs such as lamivudine and adefovir [1], [2], [3]. Emergence of drug-resistant HBV usually results in attenuated viral suppression and disease progression, and may lead to significant ...
BACKGROUND/AIMS: Chronic hepatitis has been divided into chronic persistent hepatitis, chronic lobular hepatitis and chronic active hepatitis. These terms should be discontinued in favor of etiologic terminology. The activity of necro-inflammation and the degree of fibrosis should be evaluated for grading the severity and the stage of the disease. In this study, we sought to evaluate the long-term outcome and prognostic factors of chronic hepatitis B according to the new histological classification of chronic hepatitis proposed by the Korean Study Group for the Pathology of Digestive Diseases. METHOD: One hundred and eighty-eight patients (mean age, 35.0 years; male/female 3.9:1) with biopsy-proven chronic hepatitis B were retrospectively assessed with a mean follow-up of 80.6 months. The patients were divided into a biochemically-active group and a biochemically-inactive group according to serum alanine aminotransferase (ALT) changes during follow-up periods. The development of compensated ...
TARGET-HBV is timely given the renewed interest in finding a cure for hepatitis B. Chronic hepatitis B is characterized by fluctuations in virus replication and disease activity; thus, while guidelines exist, management of individual patients can be nuanced. Data on a large cohort of hepatitis B patients managed in the real-world will provide insights into the course of this disease and guide the use of future therapies. Anna Lok, MD Ranked as the second leading cause of cancer deaths, chronic hepatitis B is the primary cause of liver cancer as an estimated 30 million people world-wide will become newly infected with the disease each year. With the increasing number of available treatments, important questions still remain regarding the HBV population at risk and current practice patterns.. Management of chronic HBV is perceived as a complex paradigm that balances the benefits of long-term suppression of HBV replication with the inconvenience and potential adverse events associated with ...
In patients with chronic hepatitis B infection, treatment with pegylated interferon has effected a fast and significant decline in hepatitis B virus RNA.
While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.
Chronic Hepatitis B Infection virus is one of the biggest enemies of the liver. It causes infections can cause severe malfunction of the liver, like scarring of the liver and liver failure.
Two large phase III trials comparing treatment with telbivudine and lamivudine over a 2-year period were conducted in adult patients with CHB. The GLOBE study (NV-02B-007, 007 ), conducted in 20 countries, compared these two antiviral agents in 1367 (921 HBeAg-positive) patients.6 A similarly designed study (NV-02B-015, 015 ) was conducted in China and enrolled 332 (290 HBeAg-positive) patients.7 In both studies, treatment with telbivudine for 2 years demonstrated significantly greater antiviral effects, compared with lamivudine, in both HBeAg-positive and HBeAg-negative patients ...
HIV Med 2005; 6(Suppl 2): 96-106. 5 Brook G, Main J, Nelson M et al. British HIV Association guidelines for the management of coinfection with HIV-1 and selleck chemicals llc hepatitis B or C virus 2010. HIV Med 2010; 11: 1-30. 6 Tedder RS, Rodger AJ, Fries L et al. The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. Clin Infect Dis 2013; 56: 951-960. 7 Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011; 16: 1169-1186. 8 Tanwar S, Dusheiko. G. Is there any value to hepatitis B virus genotype analysis? Curr Gastroenterol Rep 2012; 14: 37-46. 9 Flink HJ, van Zonneveld M, Hansen BE GSK1120212 purchase et al. Treatment with peg-interferon alpha-2b for HBeAg- positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303. 10 Soriano V, Mocroft A, Peters L et al. for EuroSIDA. Predictors of hepatitis B virus ...
FOSTER CITY, Calif., Feb 27, 2003 (BUSINESS WIRE) --. Treatment Reduces Signs of Disease Progression in Patients with Chronic Hepatitis B. Gilead Sciences (Nasdaq:GILD) today announced the publication of results from two studies evaluating the safety and efficacy of Hepsera(TM) (adefovir dipivoxil 10 mg), Gileads once-daily oral antiviral for the treatment of chronic hepatitis B, in the February 27 edition of the New England Journal of Medicine (NEJM). In both studies (437 and 438), Hepsera significantly reduced liver damage and improved liver function compared to placebo. Results from these studies show that Hepsera provides effective and well-tolerated long-term therapy for patients with chronic hepatitis B. Chronic hepatitis B is a serious disease caused by the hepatitis B virus (HBV), which attacks the liver. Chronic hepatitis B infection can lead to potentially fatal complications such as cirrhosis and liver cancer, and is one of the leading causes of death worldwide. Over 400 million ...
Background: Chronic hepatitis B (CHB) infection is one of the important causes of hepatocellular carcinoma (HCC) in Thailand, involved in the pathogenesis and leading to a development of HCC with or without cirrhotic changes of the liver. This study was aimed to investigate the predictive factors for HCC among CHB patients in a tertiary care center in Thailand. Materials and Methods: We conducted a retrospective study of CHB patients with or without HCC during the period of January 2009 and December 2014 at Thammasat University Hospital, Pathumthani, Thailand. Data on clinical characteristics, biochemical tests and radiologic findings were collected from review of medical records. Results: A total of 266 patients were diagnosed with CHB in Thammasat university hospital during the study period. However, clinical information of only 164/266 CHB patients (98 males, 66 females with mean age of 49.4 years) could be completely retrieved in this study. The prevalence of HCC in CHB infection in this study
To date no network meta-analysis (NMA) has accounted for baseline variations in viral load when assessing the relative efficacy of interventions for chronic hepatitis B (CHB). We undertook baseline-adjusted and unadjusted analyses using the same data to explore the impact of baseline viral load (BVL) on CHB treatment response. We searched Embase, Medline, Medline in Process and the Cochrane CENTRAL databases for randomised clinical trials (RCTs) of monotherapy interventions at licensed doses for use in CHB. Search strategies comprised CHB disease and drug terms (a combination of controlled vocabulary and free text terms) and also a bespoke RCT filter. The NMA was undertaken in WinBUGs using fixed and random effects methods, using data obtained from a systematic review. Individual patient data (IPD) from an entecavir clinical trial were used to quantify the impact of different baseline characteristics (in particular undetectable viral load (UVL) at 1 year) on relative treatment effect. Study level mean
Background: Hepatitis B is an immune response-mediated disease. The aim of this study was to explore the differences of ratios of T-helper (Th) 2 cells to Th1 cells and cytokine levels in acute hepatitis B (AHB) patients and chronic hepatitis B virus (HBV)-infected patients in immune-tolerance and immune-active phases. Methods: Thirty chronic HBV-infected patients in the immune-tolerant phase (IT group) and 50 chronic hepatitis B patients in the immune-active (clearance) phase (IC group), 32 AHB patients (AHB group), and 13 healthy individuals (HI group) were enrolled in the study. Th cell proportions in peripheral blood, cytokine levels in plasma, and serum levels of HBV DNA, hepatitis B surface antigen, and hepatitis B e antigen were detected. Results: The Th1 cell percentage and Th2/Th1 ratio in the HBV infection group (including IT, IC, and AHB groups) were significantly different from those in HI group (24.10% ± 8.66% and 1.72 ± 0.61 vs. 15.16% ± 4.34% and 2.40 ± 0.74, respectively; all ...
FOSTER CITY, Calif., Mar 19, 2008 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion on the companys application to extend the indication for Viread(R) (tenofovir disoproxil fumarate) to include the treatment of chronic hepatitis B in adults. The application, known as a Type II variation, was submitted to European regulatory authorities in October 2007. The CHMPs positive opinion will be forwarded to the European Commission, which will amend the Marketing Authorisation for Viread in the 27 countries of the European Union to reflect the Type II variation. The European Commission generally issues an updated Marketing Authorisation within a few months following a positive CHMP recommendation. Viread represents Gileads second once-daily antiviral developed for the potential treatment of chronic hepatitis B. The active ingredient in Viread, ...
Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment Xiulan Xue,1,* Shaohang Cai,1–3,* Hongjie Ou,1 Caixia Zheng,1 Xiaolu Wu1 1Department of Infectious Diseases, First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province, 2Department of Pathology, Sun Yat-sen University Cancer Center, 3State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong Province, People’s Republic of China *These authors contributed equally to this work Introduction: Health-related quality of life (HRQoL) has emerged as an important consideration in the care of patients with chronic hepatitis B (CHB). However, whether benefits from the improved HRQoL that occurs after antiviral treatment or drug discontinuation outweigh the risks of viral relapse is an unanswered question. The aim of this study was to evaluate the HRQoL among patients with CHB during antiviral treatment and
... - Chronic hepatitis B; Liver cirrhosis; Viral suppression; Management; Guideline
BACKGROUND Liver biopsy, which is considered the gold standard for the evaluation of hepatic fibrosis in patients with chronic hepatitis B (CHB), has certain limitations. The aim of this study was to investigate the diagnostic performance of non-invasive markers of hepatic fibrosis as potential alternatives to liver biopsy. METHODS The medical records of 221 patients with a diagnosis of CHB who underwent a liver biopsy were reviewed. Indirect indicators of fibrosis were calculated for each patient based on previously described formulas [Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR), age-platelet index (API), cirrhosis discriminant score (CDS), AST-platelet ratio index (APRI), Forns index, FIB-4, Pohl score, AAR-platelet score (AARP), fibro-quotient (FibroQ), AST/platelet/Gammaglutamyl transpeptidase (GGT)/Alphafetoprotein (AFP) (APGA) index, Platelet/Age/Phosphatase (ALP)/AFP/AST (PAPAS) index, Loks model, Goteborg University Cirrhosis Index (GUCI)]. Diagnostic adequacy
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Objectives The aim of this study was to detect the YMDD mutation responsible for lamivudine resistance in chronic hepatitis B virus (HBV)-infected patients. Background HBV infection is a major global public health problem. The aim of this work was to study the relation between the detection of YMDD mutation and lamivudine resistance in chronic HBV patients. Participants and methods This study included 50 chronic hepatitis B-infected individuals classified into two groups: group I included 25 chronic HBV patients responding to lamivudine (five female and 20 male). Group II included 25 chronic HBV patients resistant to lamivudine (one female and 24 male). All participants were selected from the National Liver Institute, Menofia University. All participants were subjected to full history taking, general examination, clinical examination, abdominal ultrasonography, laboratory investigations including serum alanine aminotransferase and aspartate transaminase, serum bilirubin, serum albumin, and ...
Even though current antiviral treatments based on pegylated interferon, or nucleos(t)ide analogues, in mono or combination therapies, have demonstrated clinical benefit to HBV-infected patients, chronic hepatitis B remains a difficult-to-cure disease. An absolute cure, defined as total elimination of HBV DNA, is currently not achievable, and a functional cure characterised by sustained virological response and HBV surface antigen (HBsAg) clearance off-treatment remains a challenge. Pegylated interferon treatment can lead to a sustained virological response and HBsAg clearance off-treatment in only 3-7% of patients,1 and it is too often associated with contraindications and adverse effects. Long-term treatment with nucleos(t)ide analogues is better tolerated, but the chance to achieve a sustained virological response and HBsAg loss remains low,2 and the drugs do not eradicate intrahepatic HBV DNA.. The risk of disease progression and development of hepatocellular carcinoma in chronically ...
In approximately 9 years after initiating NA administration, 44 % (17/39) of HBeAg-negative patients and 15 % (8/55) of HBeAg-positive patients were under control without NA. In other words, more than half of HBeAg-negative and most of HBeAg-positive patients still need NA therapy, suggesting difficulty in stopping NA therapy.. In this study we adopted the APASL stopping recommendation [12]. Most of the HBeAg-negative patients (95 %) satisfied this stopping criteria, whereas only one forth of the HBeAg-positive patients (27 %) did. These results are in agreement with a study [15] reporting that seroconversion from HBeAg-positive to HBeAb-positive occurred only in 38 % of HBeAg-positive patients through 4 year-treatment of ETV. Multivariate analysis revealed that patients with lower serum HBV-DNA levels were more likely to meet the stopping criteria in concordance with the previous study [15]. Thus, patients with higher serum HBV-DNA will have difficulty to cease NA treatment once it ...
For patients with chronic hepatitis B virus, body mass index is significantly associated with increased risk of hepatocellular carcinoma, with the risk more pronounced for women than men.
Aims: The aim was to test the efficacy of a pre-S2-containing vaccine (Genhevac-B) in chronic hepatitis B (CHB). Twenty-five naive patients (22 male, three female; median age 35; range: 6-69 years) with CHB were recruited. The inclusion criteria were: hepatitis B e antigen (HBeAg) positive or HBV-DNA detectable with liquid hybridization; alanine aminotransferase (ALT) is at least 1.5-fold the upper normal limit and histological evidence of chronic hepatitis. ...
Most people are familiar with the disease Hepatitis B because of increasing today. At present, approximately 2 billion people over the world are patients of this disease. Chronic Hepatitis B is the severe form of Hepatitis B, caused due to infection HBV or hepatitis B virus that attacks liver and cause inflammation of delicate liver Read more ...
Many studies suggest that in chronic hepatitis B virus (HBV) infection regulate T (Treg) cells and interlukin-17-producing T help cells (Th17) are mutually antagonistic in the immune response. This study is aimed to reveal the cell differentiation environment and the significance of Treg and Th17 balance in the development of acute and chronic HBV infection. Ten patients with acute HBV infection (AHB) and forty-eight patients with chronic HBV infection, including 12 asymptomatic HBV carriers (HBV carriers), 18 chronic hepatitis B patients (CHB) and 18 acute-on-chronic HBV-related liver failure (ACHBLF) were enrolled. Treg and Th17 cells differentiation related cytokine levels were detected by using ELISA. Flow cytometry was employed to count the Treg and Th17 frequency in peripheral blood. Compared to health controls both AHB and ACHBLF patients favoured Th17 cell differentiation, accompanied by a higher proportion of peripheral Th17 cells (P | 0.01) and high level of interleukin-17A (IL-17A) (P | 0.01)
Of these, 60 million are expected to die prematurely of liver cancer or cirrhosis, at a rate of approximately 1 million per year 5, per year in the United States. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.
Introduction. Hepatitis B virus (HBV) infection is more frequent in patients with chronic renal disease (CRD) than in the general population. In haemodialysis patients, the prevalence ranges from 0% to 10%,1 with a wide variance between the countrys haemodialysis units. In Spain, in 2003 the prevalence of HBV infection in haemodialysis patients was estimated to be 3.1%.1 In kidney transplant patients, the prevalence of HBV infection was around 2%,2 also with a wide geographic and demographic variability.. The infection by HBV in this population has decreased since the application of prevention measures in the 1970s, and the vaccination in 1986.. The natural history of hepatitis B in the dialysis population is not well understood due to its slow progression, which may be caused by numerous factors, including coinfection with hepatitis C virus, alcohol consumption and immunosuppression. In kidney transplant patients, chronic hepatitis B progresses more aggressively than in dialysis patients; this ...